Biomea Fusion (NASDAQ:BMEA) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Biomea Fusion (NASDAQ:BMEA - Free Report) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $40.00 price target on the stock. HC Wainwright also issued estimates for Biomea Fusion's Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($3.91) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($2.45) EPS.

Several other analysts also recently commented on BMEA. D. Boral Capital restated a "buy" rating and set a $16.00 target price on shares of Biomea Fusion in a report on Wednesday, March 19th. Oppenheimer set a $10.00 price objective on shares of Biomea Fusion in a research report on Monday, March 24th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $23.91.

Biomea Fusion Trading Up 3.3 %

Shares of BMEA stock traded up $0.07 on Monday, hitting $2.02. The stock had a trading volume of 340,488 shares, compared to its average volume of 911,633. Biomea Fusion has a twelve month low of $1.85 and a twelve month high of $14.43. The company has a fifty day moving average price of $3.14 and a two-hundred day moving average price of $5.86. The firm has a market cap of $73.02 million, a P/E ratio of -0.50 and a beta of -0.26.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its earnings results on Monday, March 31st. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.19. On average, analysts expect that Biomea Fusion will post -3.93 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. boosted its holdings in Biomea Fusion by 14.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 24,005 shares of the company's stock valued at $93,000 after purchasing an additional 3,005 shares during the period. Wexford Capital LP raised its position in Biomea Fusion by 2.3% in the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company's stock valued at $517,000 after purchasing an additional 3,007 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Biomea Fusion by 0.7% during the third quarter. Geode Capital Management LLC now owns 601,479 shares of the company's stock worth $6,076,000 after purchasing an additional 4,291 shares during the period. Wells Fargo & Company MN increased its stake in shares of Biomea Fusion by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company's stock valued at $50,000 after buying an additional 4,399 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Biomea Fusion by 27.6% in the fourth quarter. JPMorgan Chase & Co. now owns 22,535 shares of the company's stock valued at $87,000 after buying an additional 4,868 shares during the period. 96.72% of the stock is currently owned by institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.